Table 2 Clinical trials of HIF Inhibitors in cancers (https://clinicaltrials.gov)

RO7070179 (EZN-2968)

Nucleic acid drug

HIF-1α

Hepatocellular Carcinoma

NCT02564614

I

Advanced Solid Tumors With Liver Metastases

NCT01120288

I

Advanced Solid Tumors or Lymphoma

NCT00466583

I

EZN-2208 (Pegylated SN-38)

Drug repurposing

HIF-1α

Neoplasms

NCT01251926

I

Advanced Solid Tumors

Lymphoma

NCT00520637

NCT00520390

I

PX-478

Small-molecule drug

HIF-1α

Advanced Solid Tumors or Lymphoma

NCT00522652

I

Melatonin

Drug repurposing

HIF-1α

Locally Advanced Oral Squamous Cell Carcinoma

NCT04137627

III

CRLX101

Drug repurposing

HIF-1α

Ovarian Cancer

Fallopian Tube Cancer

Primary Peritoneal Cancer

NCT01652079

II

Topotecan

Drug repurposing

HIF-1α

Neoplasms

NCT00117013

I

Irinotecan

Drug repurposing

HIF-1α

Refractory Solid Tumors in Children

NCT01282697

I

Digoxin

Drug repurposing

HIF-1α

Breast Cancer

NCT01763931

II

ARO-HIF2

Nucleic acid drug

HIF-2α

Advanced Clear Cell Renal Cell Carcinoma

NCT04169711

I

NKT2152

Small-molecule drug

HIF-2α

Advanced Clear Cell Renal Cell Carcinoma

NCT05119335

I/II

PT2385

Small-molecule drug

HIF-2α

Recurrent Glioblastoma

NCT03216499

II

VHL Disease-Associated Clear Cell Renal Cell Carcinoma

NCT03108066

II

Advanced Clear Cell Renal Cell Carcinoma

NCT02293980

I

Renal Cell Carcinoma

NCT04989959

I

DFF332

Small-molecule drug

HIF-2α

Advanced/Relapsed Renal Cancer & Other Malignancies

NCT04895748

I

Belzutifan

Small-molecule drug

HIF-2α

Pheochromocytoma/Paraganglioma

Pancreatic Neuroendocrine Tumor

NCT04924075

II

Carcinoma, Renal Cell

NCT04846920

I

MBM-02

Small-molecule drug

HIF

Glioblastoma Multiforme

NCT04874506

II

Prostate Cancer Recurrent

Biochemical Recurrent Prostate Cancer

NCT04876755

II